Healing & Repair
Site-only / unverified FDA safety flag Site-only / unverified Anti-inflammatory Immunity
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10 mg
Dosing window: Anytime
Receptor / target: Alpha-MSH
Properties: Not stated
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-6 | 200mcg - 500mcg daily | Standard protocol for systemic inflammation or gut repair. |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 200 mcg 1x Daily | |
| Week 2 | 300 mcg 1x Daily | |
| Week 3 | 400 mcg 1x Daily | |
| Weeks 4-8 | 500 mcg 1x Daily |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: Injury Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 500 mcg 2-3x Daily | Administer at or near the injury or inflammation site. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Repair protocols depend on injury type, timing, loading, inflammation, and angiogenesis risk. Rodent or cell data can suggest a mechanism, but it does not prove a human dose or replace rehab and diagnosis. Entry context: target (Alpha-MSH); route Subcutaneous; timing Anytime. Site-only/low dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added.
Independent evidence
Independent safety notes: FDA states it has not identified human exposure data for KPV administered by any route.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Known hypersensitivity to KPV, alpha-MSH-derived peptides, or any formulation excipients. Site-only / unverified
- Concurrent use of immunosuppressive biologic agents (TNF-alpha inhibitors, IL-6 inhibitors, JAK inhibitors): additive anti-inflammatory pathway inhibition may push the immune response below the threshold needed for pathogen defense; theoretical but warrants clinical consideration. Site-only / unverified
- Concurrent corticosteroid use: overlapping NF-kB suppression; the additive anti-inflammatory effect may mask warning signs of infection or worsen immune suppression. Site-only / unverified
- Active infections requiring a robust acute immune response: KPV's NF-kB inhibition, while selective, may blunt cytokine response to active bacterial or viral infections at high doses. Site-only / unverified
- Pregnancy: no clinical safety data; melanocortin receptor signaling has developmental implications. Site-only / unverified
- Breastfeeding: no established safety data. Site-only / unverified
- Pediatric use: safety not established. Site-only / unverified
- PepT1-negative intestinal conditions: rare congenital PepT1 deficiency would abolish oral/enteric KPV activity. Site-only / unverified
Side effects (site-sourced)
- Mild injection site redness and irritation: the most commonly reported adverse effect; localized erythema at the subcutaneous administration site; transient; self-resolving. Site-only / unverified
- Mild gastrointestinal discomfort: particularly with oral or higher-dose administration; nausea, loose stools, or abdominal cramping; more common in the first week. Site-only / unverified
- Temporary fatigue: reported in a minority of subjects; likely related to systemic inflammatory modulation during early treatment. Site-only / unverified
- Headache: uncommon; transient. Site-only / unverified
- Skin flushing: rare; mild; may reflect residual melanocortin receptor activity. Site-only / unverified
- Mild dizziness: infrequent; mechanism unclear. Site-only / unverified
- Temporary appetite changes: rare; MC4R activity (which KPV may weakly engage) has minor effects on appetite regulation. Site-only / unverified
- Potential blunting of acute immune response at very high doses: KPV's NF-kB inhibition is dose-dependent; at supraphysiologic doses, the anti-inflammatory effect could theoretically impair the acute phase immune response to active infection. Site-only / unverified
- Allergic reactions to compounding excipients: redness, hives, stinging at injection site; relates to the compounding vehicle rather than KPV itself. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)tri-heal-blend